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Ovarian cancer is responsible for the majority of gyne-
cologic cancer deaths. Despite improvements in surgical
approaches and the refinement of first-line cytotoxic
combinations, the majority of patients diagnosed with
advanced stage ovarian cancer eventually succumb to
tumor recurrence. Thus, novel therapeutic approaches
are desperately needed for this disease. With the growing
recognition of the importance of immune modulation in
ovarian cancer development, various immune-based
modalities have been actively explored. Here we present
a novel adoptive immunotherapy strategy that utilizes
chimeric antigen receptor (CAR) engineered T cells
reprogrammed to target L1-CAM. Our studies demon-
strate L1-CAM is an ovarian tumor associated-antigen -
it is over-expressed on a panel of established and primary
ovarian cancer cell lines, as well as detected at various
levels in the majority of the primary ovarian tumor spe-
cimens interrogated (39 of 40 cases). Importantly,
L1-CAM was not expressed on normal ovary suggesting
an excellent window opportunity for tumor specific
targeting. We achieved HLA-independent L1-CAM
targeting by engineering T cells to express a CAR, desig-
nated as CE7R, comprised of an scFv derived from the
L1-CAM-specific monoclonal antibody CE7 linked to
the CD28 co-stimulatory and CD3-zeta endodomains.
We report that these genetically re-programmed CE7R+
T cells specifically and efficiently killed a panel of
L1-CAM+ human ovarian cancer cells in vitro including
OVCAR-3, MADH2744, Caov3, SKOV3; but did not kill
L1-CAM-negative cell lines such as A2780. In concor-
dance with the cytolytic assay, the CE7R+ T cells were
activated to produce proinflammatory cytokines such as
IFNg, TNFa and GM-CSF upon co-culture with
L1-CAM+ tumor cell lines, but failed to do so upon
stimulation with L1-CAM-negative cells. Moreover,
CE7R+ T cells also lysed primary cultured L1-CAM
positive cancer cells derived from ovarian cancer
patients’ ascites. Importantly, a single dose intraperi-
toneal administration of CE7R+ T cells induced regression
of i.p. established OVCAR-3 xenograft tumor growth
in mice. For the first time, these results demonstrate
L1-CAM is amenable to targeting by CAR+ T cells and
support the potential of this CAR-based adoptive T cell
immunotherapeutic approach in treating ovarian cancer.
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